Rodent Model of PTSD-like conditions-Role of Noradrenergic System

Information

  • Research Project
  • 7882191
  • ApplicationId
    7882191
  • Core Project Number
    R15MH090541
  • Full Project Number
    1R15MH090541-01
  • Serial Number
    90541
  • FOA Number
    PA-06-042
  • Sub Project Id
  • Project Start Date
    4/15/2010 - 14 years ago
  • Project End Date
    8/31/2014 - 9 years ago
  • Program Officer Name
    WINSKY, LOIS M.
  • Budget Start Date
    4/15/2010 - 14 years ago
  • Budget End Date
    8/31/2014 - 9 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/14/2010 - 14 years ago

Rodent Model of PTSD-like conditions-Role of Noradrenergic System

DESCRIPTION (provided by applicant): The overall goal of this grant is to understand the neurobiological mechanisms that underlie posttraumatic stress disorder (PTSD)-like conditions as well as the treatment of these conditions in an established rodent model. The specific aims are: 1) to delineate the immediate and long term effects of a traumatic experience on sleep architecture, freezing behavior and heart rate changes in Wistar-Kyoto (WKY) and Wistar (WIS) rats and correlate these changes with noradrenergic activity in the prefrontal cortex, amygdala and hippocampus;2) to evaluate whether treatments with prazosin or propranolol will differentially ameliorate the behavioral and neuroanatomical outcomes measured in Aim 1 in the vulnerable WKY vs. resistant WIS rats. The basic approach will be to use fear conditioning, accomplished by pairing tones (conditioned stimulus [CS]) with foot shocks (unconditioned stimulus [US]), to assess conditioned fear. Freezing, ultrasonic vocalization, heart rate and sleep behavior will be compared between the two strains. Treatment with prazosin (11 adrenoceptor antagonist) or propranolol (21 adrenoceptor antagonist) will take place at appropriate timings relative to the initial triggering and subsequent exacerbating events. Following sleep recording, animals will be decapitated, and trunk blood and brains removed for analysis of stress hormones and noradrenergic pre and post-synaptic receptors. It is expected that PTSD-like symptoms will be more pronounced in the stress-reactive WKY rats compared to the more stress-resistant WIS rats. Furthermore, these strain differences will be related to altered expression and function of 11 and 21-adrenoceptors in the prefrontal cortex, amygdala and hippocampus, the three brain regions strongly implicated in the pathophysiology of PTSD. By defining the noradrenergic pathways by which these drugs alleviate PTSD-like conditions, our studies will provide relevant information which would otherwise be difficult to obtain from clinical studies, and will enhance our ability to develop effective treatment strategies to improve the quality of life for PTSD patients. PUBLIC HEALTH RELEVANCE: Our proposed studies are designed to provide information regarding the noradrenergic mechanisms that underlie posttraumatic stress disorder (PTSD)-like conditions in the Wistar-Kyoto rat, an established animal model for studying stress-related psychiatric disorders. The basic approach will be to use a fear conditioning procedure, followed by measurements of freezing, ultrasonic vocalization, heart rate and sleep behaviors. Following sleep recordings, noradrenergic pre and post-synaptic receptors will be measured in the brains of these animals. Treatment with prazosin (11 adrenoceptor antagonist) or propranolol (21 adrenoceptor antagonist) will take place at appropriate timings relative to the initial triggering and subsequent exacerbating events. By defining the noradrenergic pathways by which these drugs alleviate PTSD-like conditions, our studies will provide relevant information which would otherwise be difficult to obtain from clinical studies, and will enhance our ability to develop effective treatment strategies to improve the quality of life for PTSD patients.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R15
  • Administering IC
    MH
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    213750
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    242
  • Ed Inst. Type
    SCHOOLS OF PHARMACY
  • Funding ICs
    NIMH:213750\
  • Funding Mechanism
    Research Projects
  • Study Section
    PMDA
  • Study Section Name
    Pathophysiological Basis of Mental Disorders and Addictions Study Section
  • Organization Name
    UNIVERSITY OF THE SCIENCES PHILADELPHIA
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    079497681
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191044418
  • Organization District
    UNITED STATES